ADA 2026: Retatrutide TRANSCEND-T2D-1 & TRIUMPH-1 Panel Preview

Event: ADA 86th Scientific Sessions · June 6-10, 2026 · New Orleans, LA · Ernest N. Morial Convention Center

The American Diabetes Association's 86th Scientific Sessions, held June 6-10, 2026 in New Orleans, will feature the most detailed public presentation to date of retatrutide's Phase 3 data. The TRANSCEND-T2D-1 and TRIUMPH-1 results — beyond what Lilly has shared in topline press releases — will be presented in a dedicated symposium on Saturday, June 6, from 1:30-3:00 p.m. in Great Hall A.

The Symposium

Title: Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)

Date: Saturday, June 6, 2026 Time: 1:30 – 3:00 p.m. (Central Time) Location: Great Hall A, Ernest N. Morial Convention Center, New Orleans On-demand access: Recorded presentations available to registered participants June 10 – August 10, 2026

Confirmed Speakers and Topics

For the full ADA 2026 program, see ADA Meeting News.

What to Expect

1. Full TRANSCEND-T2D-1 results beyond the topline. Lilly's March 19 press release reported A1C reduction of 1.7-2.0% and 16.8% weight loss at 12 mg. The ADA session is expected to add:

• Detailed subgroup analyses (by baseline A1C, diabetes duration, BMI)
• Glycemic targets (% reaching A1C below 6.5% and 7.0%)
• Detailed safety and tolerability data
• Body composition changes (fat mass vs. lean mass)
• Hypoglycemia rates (relevant given the glucagon receptor activation)
• Cardiometabolic changes (lipids, blood pressure, hsCRP)

See our TRANSCEND-T2D-1 page for the topline summary.

2. TRIUMPH-1 first look. TRIUMPH-1 is the largest of the Phase 3 obesity registration trials and the most important for the eventual FDA filing. As of May 2026, full topline results have not been publicly released — ADA 2026 may be the venue for that disclosure. The TRIUMPH-1 portion of the session is expected to cover:

• Mean weight loss at 9 mg and 12 mg doses
• Comparison to historical Phase 3 trials of semaglutide and tirzepatide
• Cardiometabolic and quality-of-life secondary endpoints
• Safety, including the dysesthesia signal first observed in TRIUMPH-4

3. Triple-agonist mechanism deep dive. Dr. Campbell's talk on glucagon receptor agonism is expected to address how the third receptor distinguishes retatrutide from existing dual (tirzepatide) and single (semaglutide) agonists — particularly for hepatic metabolism, energy expenditure, and lean mass preservation. This is the mechanistic question that has driven the most analyst interest in retatrutide.

Why ADA 2026 Matters

Regulatory signal. Lilly has guided that retatrutide regulatory submissions will occur in 2026. The ADA 2026 session is one of the last major scientific venues before that filing, and the data presented here will shape physician expectations heading into the FDA review.

Insurance coverage trajectory. Payer formulary decisions begin with the scientific data presented at conferences like ADA and the resulting published peer-reviewed literature. Strong TRIUMPH-1 results presented here could accelerate coverage decisions ahead of approval.

Direct comparison with the rest of the obesity drug landscape. ADA 2026 also includes sessions on tirzepatide's long-term outcomes, oral GLP-1s (orforglipron), and survodutide. Retatrutide will be evaluated by the diabetes community against the full competitive set in real time.

How to Follow the Data

• Live coverage of presentations will be available through ADA Meeting News and the major medical news outlets (CNBC, BioPharma Dive, Endpoints News, STAT News).
• Full publications are typically released in New England Journal of Medicine, The Lancet, or Diabetes Care in coordination with major conference presentations.
• Our News page will be updated throughout the week with each major readout from the session.

Frequently Asked Questions

Sources

• Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1 — ADA Meeting News (April 27, 2026)
• American Diabetes Association — 86th Scientific Sessions Program
• Eli Lilly and Company — TRANSCEND-T2D-1 topline press release (March 19, 2026)

Medical disclaimer: This page is a preview of an upcoming scientific session and may include speculation about expected content. Retatrutide is not FDA approved. This is informational only, not medical advice. glp3.wiki is not affiliated with Eli Lilly, the ADA, or any pharmaceutical company.